Eli Lilly discovers, develops, manufactures, and markets products in two business segments: human pharmaceutical products and animal health products. Co.'s human pharmaceutical products include: neurosciences products, endocrinology products, oncology products, and cardiovascular products. Co.'s animal health products is comprised of products for food animals, which include Rumensin®, a cattle feed additive, and Tylan®, an antibiotic used to control certain diseases in cattle, swine, and poultry; as well as products for companion animals, which include Trifexis® and Comfortis®, a chewable tablet for dogs; and Reconcile®, for treatment of canine separation anxiety.
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.